310 related articles for article (PubMed ID: 28038383)
1. Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients.
Zhang Y; Cai P; Li L; Shi L; Chang P; Liang T; Yang Q; Liu Y; Wang L; Hu L
Int Immunopharmacol; 2017 Feb; 43():210-218. PubMed ID: 28038383
[TBL] [Abstract][Full Text] [Related]
2. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.
Huang YH; Zhu C; Kondo Y; Anderson AC; Gandhi A; Russell A; Dougan SK; Petersen BS; Melum E; Pertel T; Clayton KL; Raab M; Chen Q; Beauchemin N; Yazaki PJ; Pyzik M; Ostrowski MA; Glickman JN; Rudd CE; Ploegh HL; Franke A; Petsko GA; Kuchroo VK; Blumberg RS
Nature; 2015 Jan; 517(7534):386-90. PubMed ID: 25363763
[TBL] [Abstract][Full Text] [Related]
3. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
[TBL] [Abstract][Full Text] [Related]
4. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8
Lake CM; Voss K; Bauman BM; Pohida K; Jiang T; Dveksler G; Snow AL
Cell Death Dis; 2021 Apr; 12(4):400. PubMed ID: 33854046
[TBL] [Abstract][Full Text] [Related]
5. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
6. Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas.
Li J; Liu X; Duan Y; Liu Y; Wang H; Lian S; Zhuang G; Fan Y
Med Sci Monit; 2017 Jul; 23():3593-3602. PubMed ID: 28736431
[TBL] [Abstract][Full Text] [Related]
7. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
8. TIM-3 and CEACAM1 do not interact in cis and in trans.
De Sousa Linhares A; Kellner F; Jutz S; Zlabinger GJ; Gabius HJ; Huppa JB; Leitner J; Steinberger P
Eur J Immunol; 2020 Aug; 50(8):1126-1141. PubMed ID: 32222966
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
10. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
[TBL] [Abstract][Full Text] [Related]
11. TIM-3 and CEACAM1 are Prognostic Factors in Head and Neck Squamous Cell Carcinoma.
Yang F; Zeng Z; Li J; Ren X; Wei F
Front Mol Biosci; 2021; 8():619765. PubMed ID: 34368221
[No Abstract] [Full Text] [Related]
12. Modulation of Tim-3 Expression by Antigen-Dependent and -Independent Factors on T Cells from Patients with Chronic Hepatitis B Virus Infection.
Dong J; Yang XF; Wang LX; Wei X; Wang AH; Hao CQ; Shen HJ; Huang CX; Zhang Y; Lian JQ
Front Cell Infect Microbiol; 2017; 7():98. PubMed ID: 28401068
[TBL] [Abstract][Full Text] [Related]
13. Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma.
Su H; Xie H; Dai C; Ren Y; She Y; Xu L; Chen D; Xie D; Zhang L; Jiang G; Chen C
Lung Cancer; 2018 Jul; 121():18-24. PubMed ID: 29858021
[TBL] [Abstract][Full Text] [Related]
14. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
15. An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer.
Takano S; Saito H; Ikeguchi M
Surg Today; 2016 Nov; 46(11):1341-7. PubMed ID: 26801344
[TBL] [Abstract][Full Text] [Related]
16. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
[TBL] [Abstract][Full Text] [Related]
18. A Deficit of CEACAM-1-Expressing T Lymphocytes Supports Inflammation in Primary Progressive Multiple Sclerosis.
Piancone F; Saresella M; Marventano I; La Rosa F; Caputo D; Mendozzi L; Rovaris M; Clerici M
J Immunol; 2019 Jul; 203(1):76-83. PubMed ID: 31142599
[TBL] [Abstract][Full Text] [Related]
19. Engineering a CEACAM1 Variant with the Increased Binding Affinity to TIM-3 Receptor.
Hajihassan Z; Mohammadpour Saray M; Yaseri A
Iran Biomed J; 2023 Jul; 27(4):191-8. PubMed ID: 37525418
[TBL] [Abstract][Full Text] [Related]
20. [Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer].
Ji P; Chen D; Bian J; Xia R; Song X; Wen W; Zhang X; Zhu Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):808-11. PubMed ID: 26062425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
